The Gene Therapy Spree Rolls on With $3 Billion Astellas Deal

This is the web version of Brainstorm Health Daily, Fortune’s daily newsletter on the top health care news. To get it delivered daily to your in-box, sign up here. Good afternoon, readers. Biogen paid $800 million for Nightstar Therapeutics. Drug giant Roche wants to pony up $4.3 billion deal for Spark Therapeutics in a deal that’s now
Complete Reading

Happy Monday, readers! I hope you enjoyed your weekend. Fortune‘s 2019 Global Forum began on Monday in Paris. I encourage readers to catch up on the panels, one-on-one interviews, and conversations with some of the most consequential figures in business and government. On the health care front, here’s what I found intriguing: A back-and-forth between
Complete Reading

“We need to reconnect the head to the body.” That was one of the themes that Bernard J. Tyson, the charismatic and visionary CEO of Kaiser Permanente, would return to time and again in his seemingly tireless efforts to rethink American health care. Tyson, who passed away in his sleep early Sunday at the age
Complete Reading

Happy Friday, readers. In 2018, Moderna Therapeutics filed for a titanic IPO (at that point, the largest biotech public offering in history). It raised $604 million, setting the company up for an initial valuation of about $7.5 billion. But, as is the story with so many pre-market biotechs, controversy was just around the corner. Moderna’s
Complete Reading

Hello and happy hump day, readers! The reckoning has begun for the e-cigarette and vaping industry. Following increasingly urgent reports of an epidemic of youth vaping and hundreds of cases of mysterious lung illnesses—and, now, six deaths—allegedly linked to such products, the Trump administration is moving to ban flavored e-cigarettes from the market altogether. “The
Complete Reading

Happy Friday, readers! The University of California, San Francisco (UCSF) is out with a fascinating new study on why some people can, comfortably, get through their days with just four to six hours of sleep on a consistent basis. Call it the science of sleep. What drives this phenomenon (at least for a slice of
Complete Reading

A happy summer Friday to all of you. CRISPR gene-editing is about to reach yet another milestone in the U.S. Editas, alongside partner Allergan (the manufacturer of Botox which is about to be swept up in a mega-deal by biotech giant AbbVie, which in turn makes the world’s best-selling drug) will launch studies using CRISPR
Complete Reading

Folks, it’s the summer, it’s about to be America’s birthday—and we’re going to take a break here at Brainstorm Health Daily. We’ll be back in action next Monday, July 8th, with all the latest health news from the digital, policy, and business sides of the sector. In the meantime, I hope you’ll all log off
Complete Reading

Happy Monday, readers! Bristol-Myers Squibb hasn’t exactly had a pristine path to its proposed acquisition of Celgene. Sure, the legacy pharma giant racked up more than 75% of shareholder votes to approve the $74 billion acquisition following a quickly-quashed rebellion from some activist naysayers. But the company hit another hurdle in its Celgene acquisition quest
Complete Reading

The digital health funding fever is far from breaking. Venture funding for digital health firms around the world hit an all-time high of $14.6 billion in 2018, according to a new report from StartUp Health, marking the eighth consecutive year of investment growth. In the U.S. alone, health startups raked in a record $8.1 billion,
Complete Reading

Create Account



Log In Your Account